I studied biology (B. Sc.) and biochemistry (M. Sc.) at the Friedrich Schiller University Jena in Germany. Back then, I became interested in mouse models of lymphoid malignancies and how disease manifestation could be prevented. In 2018, I completed my PhD studies in the group of Christian Kosan at the biochemistry department of the University Jena, being supported by a PhD scholarship from the Carl-Zeiss Foundation.
During my PhD studies, I was trained for 6 months in state-of-the-art techniques in the lab of Tarik Möröy at the Institut de Recherches Cliniques de Montréal in Canada. The concept of epigenetic plasticity, and how pharmacological targeting influences epigenetics in cancer became one of my main topics. In pre-clinical models, I discovered three new approaches to target MYC-dependent lymphoma cells in collaborative efforts.
As a postdoc, I qualified in academic teaching which leveraged my interaction with students and the supervision of research projects. I joined the Josep Carreras Leukaemia Research Institute in 2020 to become part of a community of researchers aiming for curing blood cancers.
Joshi G et al. Dichotomous Impact of Myc on rRNA Gene Activation and Silencing in B Cell Lymphomagenesis. Cancers (Basel). 2020
Ross J et al. Deletion of the Miz-1 POZ domain increases efficacy of cytarabine treatment in T- and B-ALL/lymphoma mouse models. Cancer Research. 2019
Hartleben G et al. MYC induces TSC1 for tumor maintenance in Burkitt’s lymphoma. EMBO Journal. 2018